Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
337 results about "Osteopetrosis" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Osteopetrosis, literally "stone bone", also known as marble bone disease or Albers-Schönberg disease, is an extremely rare inherited disorder whereby the bones harden, becoming denser, in contrast to more prevalent conditions like osteoporosis, in which the bones become less dense and more brittle, or osteomalacia, in which the bones soften. Osteopetrosis can cause bones to dissolve and break.
Isoindole-imide compounds, compositions, and uses thereof
The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-alpha in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
Owner:CELGENE CORP
Isoindole-imide compounds, compositions, and uses thereof
The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-alpha in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
Owner:CELGENE CORP
Isoindole-imide compounds, compositions, and uses thereof
Owner:CELGENE CORP
Active variants of FGF with improved specificity
InactiveUS7288406B2Enhanced receptor specificityImprove in vivo activitySugar derivativesPeptide/protein ingredientsDiseaseReceptor subtype
The present invention provides active fibroblast growth factor variants demonstrating enhanced receptor subtype specificity. The preferred novel variants retain binding to FGF Receptor Type 3 (FGFR3) triggering intracellular downstream mechanisms leading to activation of a biological response. Methods of utilizing preferred FGF mutants in preparation of medicaments for the treatment of malignancies and skeletal disorders including osteoporosis and enhancing fracture healing and wound healing processes are provided.
Owner:PROCHON BIOTECH
Digital topological analysis of trabecular bone MR images and prediction of osteoporosis fractures
The invention provides method, system and device for determining trabecular bone structure and strength by digital topological analysis, and offers, for the first time, a demonstration of superior associations between vertebral deformity and a number of architectural indices measured in the distal radius, thus permitting reliable and noninvasive detection and determination of the pathogenesis of osteoporosis. A preferred embodiment provides imaging in three dimension of a region of trabecular bone, after which the 3D image is converted into a skeletonized surface representation. Digital topological analysis is applied to the converted image, and each image voxel is identified and classified as a curve, a surface, or a junction; and then associated with microarchitectural indices of trabecular bone to quantitatively characterize the trabecular bone network. The invention is applicable in vivo, particularly on human subjects, or ex vivo.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Zoledronic acid for preparing medicaments for preventing and treating osteoporosis
The invention discloses applications of zoledronic acid in preventing osteoporosis; the zoopery is providence that zoledronic acid has good preventing effect and therapeutical action to osteoporosis; zoledronic acid can be prepared into any clinically acceptable oral preparations such as tablets, capsules, granules, suspensions, dry suspensions and oral liquid, etc. so as to clinically prevent and treat osteoporosis.
Owner:王洪 +1
Method of dephosphorylating an endotoxin in vivo with alkaline phosphatase
The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of metabolic bone diseases such as osteoporosis and osteomalacia and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity in vivo.
Owner:UNIVERSITY OF GRONINGEN
Automatic contextual segmentation for imaging bones for osteoporosis therapies
An automatic contextual segmentation method which can be used to identify features in QCT images of femora, tibiae and vertebrae. The principal advantages of this automatic approach over traditional techniques such as histomorphometry are, 1) the algorithms can be implemented in a fast, uniform, non-subjective manner across many images allowing unbiased comparisons of therapeutic efficacy, 2) much larger volumes in the region of interest can be analyzed, and 3) QCT can be used longitudinally. Two automatic contextual segmentation algorithms relate to a cortical bone algorithm (CBA) and a whole bone algorithm (WBA). These methods include a preprocessing step, a threshold selection step, a segmentation step satisfying logical constraints, a pixel wise label image updating step, and a feature extraction step; with the WBA including whole bone segmentation, cortical segmentation, spine segmentation, and centrum segmentation. The algorithms are constructed to provide successful segmentations for known classes of bones with known topological constraints.
Owner:ELI LILLY & CO
Compositions and methods for use for antibodies against sclerostin
The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target in sclerostin polypeptide, characterized in that the antibody or functional protein specifically binds to sclerostin polypeptide and can increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal.
Owner:MEREO BIOPHARMA 3 LTD
Compositions and methods for use for antibodies against sclerostin
The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat disease related to bone abnormalities such as osteoporosis. An embodiment of the invention herein provides an antibody or a functional protein comprising an antigen-binding portion of said antibody for a target in sclerostin polypeptide, characterized in that the antibody or functional protein specifically binds to sclerostin polypeptide and can increase at least one of bone formation, bone mineral density, bone mineral content, bone mass, bone quality and bone strength in a mammal.
Owner:MEREO BIOPHARMA 3 LTD
Cysteine protease inhibitor
This invention relates to a cysteine protease inhibitor comprising casein which is a protein derived from milk, a partial peptide of casein, and / or hydrolysate of casein as an active ingredient. The cysteine protease inhibitor of the present invention can be used as preventive or therapeutic drug for osteoporosis, malignant hypercalcemia, breast cancer, prostate cancer, periodontitis or bacterial and viral infectious diseases, and food, drink, feed and the like.
Owner:MORINAGA MILK IND CO LTD
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
InactiveUS6465445B1Reduce riskGood effectBiocideOrganic chemistrySelective progesterone receptor modulatorOsteopetrosis
Novel methods for the medical treatment and / or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure:and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3beta,17beta-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and / or sex steroid precursor is disclosed for the medical treatment and / or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Owner:ENDORES & DEV
Anti-aging composition containing resveratrol and method of administration
InactiveUS20090163580A1Improve athletic performanceBiocideNervous disorderActive agentExercise performance
Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependant illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.
Owner:NATROL
Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss
This invention relates to pyrimidine compounds of formula (I), formula (I′), and formula (I″):and pharmaceutically acceptable salts, solvates, clathrates, and prodrugs thereof, wherein R1, R2, R3, R4, R5, U, V, W, X, Y, Z, and n are defined herein. This invention also relates to compositions comprising these compounds and methods for using them. The compounds and compositions of this invention are useful to treat or prevent disorders associated with excessive bone loss, including, without limitation periodontal disease, non-malignant bone disorders (such as osteoporosis, Pagers-disease of bone, osteogenesis imperfecta, fibrous dysplasia, and primary hyperparathyroidism) estrogen deficiency, inflammatory bone loss, bone malignancy, arthritis, osteopetrosis, and certain cancer-related disorders (such as hypercalcemia of malignancy (HCM), osteolytic bone lesions of multiple myeloma and osteolytic bone metastases of breast cancer and other metastatic cancers).
Owner:SYNTA PHARMA CORP
Compositions and methods of the treatment of obesity and osteoporosis
InactiveUS20100093678A1Promote osteogenesisReduce adipogenesisBiocideMetabolism disorderOsteopetrosisVitamin
The present invention relates to naturally occurring compositions comprising vitamin D3 or related analog and methods for treating obesity and / or osteoporosis and reducing body fat or enhancing a bone graft in patients in need thereof.
Owner:UNIV OF GEORGIA RES FOUND INC
Indazolinone compositions useful as kinase inhibitors
The present invention provides compounds of formula I:These compounds, and pharmaceutically acceptable compositions thereof, are useful generally as kinase inhibitors, particularly as inhibitors of PRAK, GSK3, ERK2, CDK2, MK2, SRC, SYK, and Aurora-2. Accordingly, compounds and compositions of the invention are useful for treating or lessening the severity of a variety of disorders, including, but not limited to, heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, destructive bone disorders such as osteoporosis, proliferative disorders, infectious diseases and viral diseases.
Owner:VERTEX PHARMA INC
Anti-human vitronectin antibody and methods for making the same
InactiveUS20050048057A1Animal cellsImmunoglobulins against animals/humansVitronectinPercent Diameter Stenosis
The present invention relates to a method for raising a monoclonal antibody against human vitronectin and the purified anti-vitronectin antibody produced by this method. The antibody of the present invention is useful as both a research tool and as an agent for the diagnosis and treatment of cancers, cardiovascular diseases, particularly atherosclerosis and restenosis, osteoporosis, and inflammatory diseases.
Owner:MOLECULAR INNOVATIONS
Co-administration of steroids and zoledronic acid to prevent and treat side effects from zoledronic acid infusion
ActiveUS20110263537A1Prevent and treat side effectBiocideOrganic active ingredientsPaget DiseaseSide effect
Zoledronic Acid is used for treatment of hypercalcemia of malignancy, for the treatment of bone metastasis associated with malignancies such as prostate and breast cancer, for the prevention of and treatment of osteoporosis and for the treatment of Paget's disease. Administration of Zoledronic Acid is complicated by what is described as “post-dosing syndrome” (PDS) and osteonecrosis of the jaw (ONJ). Inflammation may be the cause of these side effects, which could be decreased by the co-administration of steroids. This application is a method of use patent for the co-administration of steroids (oral, IV, IM, rectal, or by inhalation) with Zoledronic Acid and a composition of matter patent for mixing Methyl Prednisolone with Zoledronic Acid for infusion.
Owner:DESAI KETAN
Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
InactiveUS6670346B1Reduce riskBiocideOrganic chemistrySelective progesterone receptor modulatorIn vivo
Novel methods for the medical treatment and / or inhibition of the development of osteoporosis, breast cancer, hypercholesterolemia, hyperlipidemia or atherosclerosis in susceptible warm-blooded animals including humans involving administration of selective estrogen receptor modulator particularly compounds having the general structure:and an amount of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone sulfate, androst-5-ene-3beta,17beta-diol and compounds converted in vivo to one of the foregoing presursor. Further administration of bisphosphonates in combination with selective estrogen receptor modulators and / or sex steroid precursor is disclosed for the medical treatment and / or inhibition of the development of osteoporosis. Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.
Owner:ENDORES & DEV
Medicine for treating osteoporosis and its preparing process
The medicine for treating osteoporosis is prepared with nine kinds of Chinese medicinal materials including prepared fleeceflower root, epimedium, prepared rhizome of rehmannia, tortoise shell, morinda root, etc. The preparation process includes the steps of: crushing and sieving partial Chinese yam, decoction, collecting volatile oil, merging decoctions, filtering, spray drying to obtain medicine powder, spraying the volatile oil to the powder, low temperature drying, mixing, capsulizing, etc. The present invention has the functions of invigorating liver and kidney, promoting generation oflife essence and blood and strengthening physique and thus has obvious curative effect on osteoporosis.
Owner:广东安诺药业股份有限公司
Therapeutic benzothiazole compounds
Compounds of the formula (I) for use as an estrogen receptor -β-selective ligand are described wherein: X is O or S; and R1, R3-R6 are as described in the specification. The use of these compounds in treating Alzheimer's disease, anxiety disorders, depressive disorders, osteoporosis, cardiovascular disease, rheumatoid arthritis and prostate cancer is described; as are processes for making them.
Owner:BARLAAM BERNARD +3
Osteoporosis treatment
There is disclosed a process of treating or alleviating the symptoms of pathological conditions in which bone density is decreased, which comprises inhibiting, in a mammalian patient suffering from such a condition, the formation in vivo of a tertiary complex of IL-11, its cell surface membrane receptor and the cell surface glycoprotein gp130. Examples of such substances are recombinant soluble IL-11 receptor mutants modified, as compared with native IL-11 receptor, at their gp130 binding site, and peptides which can interact with IL-11. The process of the invention not only inhibits bone resorption and hence bone loss, but also increases the process of bone formation to increase bone density.
Owner:HAMILTON CIVIC HOSPITALS RES CENT +2
Use of anti-IL-20 antibody for treating osteoporosis
Owner:LBL BIOTECH INC
Pharmaceutical compositions and preparations for treatment of metabolic bone disease
The present invention relates to a pharmaceutical composition for the treatment of metabolic bone disease and the method of preparation thereof, and more particularly, to an improved pharmaceutical composition for the therapeutic treatment of metabolic disease and the method of preparation thereof, wherein said composition is prepared as a composite pharmaceutical agent which comprises calcitriol; which reduces the rate of spine fractures and increases bone density; alendronate, a bone resorption inhibitor, as two main active ingredients in an optimal mixing ratio to exert the greatest synergistic therapeutic effect; and adequate amount of other additives such as a resorption fortifier of alendronate. Thereof, the pharmaceutical composition according to the present invention can inhibit hypercalcemia caused when administered by calcitriol alone, compensate the inhibitory activity of bone remodeling caused by alendronate due to the presence of calcitriol, and improve drug compliance associated with the usual difficulty in administration as well as a side effect in esophagus, thus effectively preventing the occurence of osteoporosis.
Owner:YUYU IND
Agent for anti-osteoporosis
InactiveUS6440446B1Outstanding anti-osteoporosisCarbohydrate active ingredientsPill deliverySide effectAdditive ingredient
An orally or parenterally administrable agent for anti-osteoporosis, comprising trehalose as an effective ingredient and optionally another ingredients, that exerts a satisfactory therapeutic / prophylactic effect on osteoporosis with lesser side effects.
Owner:HAYASHIBARA BIOCHEMICAL LAB INC
Combination therapy for conditions leading to bone loss
InactiveUS7005413B1Increase bone densityPromoting bone accumulationPeptide/protein ingredientsAntibody mimetics/scaffoldsCombined Modality TherapyTumor necrosis factor receptor
The present invention discloses a novel secreted polypeptide, termed osteoprotegerin, which is a member of the tumor necrosis factor receptor superfamily and is involved in the regulation of bone metabolism. Also disclosed are nucleic acids encoding osteoprotegerin, polypeptides, recombinant vectors and host cells for expression, antibodies which bind OPG, and pharmaceutical compositions. The polypeptides are used to treat bone diseases characterized by increased resorption such as osteoporosis. Methods of treatment are described using the polypeptides in conjunction with various agents, including IL-1 inhibitors, TNF-α inhibitors, and serine protease inhibitors.
Owner:AMGEN INC
Medicine for preventing and curing rachitis and osteoporosis and method for preparing the same
InactiveCN1466976AGood effect of nourishing spleen and kidneyImprove immunityOrganic active ingredientsInanimate material medical ingredientsOsteopetrosisExcipient
A medicine in the form of particle, tablet or capsule for preventing and treating rachitis and osteoporosis is prepared from VD, medicinal calcium, and 10 Chinese-medicinal materials including pilose asiabell root, astragalus root, ophiopogon root, white atractylodes rhizome, etc through decocting said Chinese-medicinal materials, concentrating, mixing with others, excipient and flavouring.
Owner:JIANMIN PHARMA GRP CO LTD
beta- and gamma-diketones and gamma-hydroxyketones as WNT/beta-catenin signaling pathway activators
ActiveUS8609717B2Increasing cell and tissue regenerationIncrease cell and tissue regenerationBiocideSenses disorderDiseaseBeta-catenin
Owner:BIOSPLICE THERAPEUTICS INC
Calcium phosphate-based materials containing zinc, magnesium, fluoride and carbonate
InactiveUS7419680B2Reduce developmentStop progressBiocideOrganic active ingredientsCalcium biphosphateMedicine
Compositions useful in the prevention and treatment of osteoporosis and for bone and fracture repair. Slow-releasing calcium phosphate-based materials are disclosed, incorporating Mg, Zn, F and carbonate, which will promote bone formation and inhibit bone resorption and thus be agents for the cited uses.
Owner:NEW YORK UNIV
Kit for detecting juvenile osteoporosis
ActiveCN106868125AEffective early diagnosisReduce deformity rateMicrobiological testing/measurementDNA/RNA fragmentationJuvenile osteoporosisCrowds
The invention discloses a kit for detecting juvenile osteoporosis. According to the kit, an obvious mutant site which is a site 1020 is discovered to exist in a DKK1 gene in a patient suffering from the juvenile osteoporosis and a normal crowd through genetic comparison. Through detecting the mutant site, particularly provided one pair of specific primer pairs, a human body which suffers from the juvenile osteoporosis can be specifically identified. Compared with the method in the prior art, a detection method has the advantages of being quick for detection, accurate and quick, and is suitable to popularize and use.
Owner:SUZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com